Sharps Technology Appoints Industry Sales and Manufacturing Leader Ben Scheu as Senior Director of Sales
12 Luglio 2023 - 2:33PM
Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and
“STSSW”), an innovative medical device and drug delivery Company
offering patented, best-in-class syringe products, is pleased to
announce the appointment of Ben Scheu as Senior Director of Sales
to lead commercial operations as the Company prepares to launch
products to the market.
Robert Hayes, Sharps Technology Chief Executive
Officer, commented: “With an extensive career leading companies
that manufacture pharmaceutical packaging products and a proven
track record of driving revenue growth, Ben will play an integral
role in accelerating Sharps’ expansion and solidifying the
Company’s position in the market. I worked with Ben when he was the
President and CEO of Centor, Inc., a business unit of Gerresheimer,
and saw significant growth through his leadership in the Company’s
prescription container and medication dispensing units to become
the market leader in those segments. I am confident in his ability
to expand our market presence with an initial focus on launching
our Securegard® disposable smart safety syringe product line, and
then leading the team that will introduce Sharps’ next-generation
polymer-based prefilled syringe systems. Ben is well-positioned to
contribute to our long-term success and we look forward to his
leadership.”
Mr. Scheu has held executive leadership
positions in prominent healthcare companies and has demonstrated
his ability to drive sales growth and develop effective commercial
strategies. Prior to joining Sharps, Mr. Scheu served as President
and CEO of Centor Inc., a pharmaceutical packaging manufacturing
division of Gerresheimer with a complete line of regulatory
compliant prescription containers for medication
dispensing, packaging for robotic automation and standard and
custom imprinted closures. At Centor, he oversaw significant
revenue growth that led their company to achieve a market leading
position in the prescription container and medication dispensing
product segment. Additionally, Mr. Scheu served as COO of The
Waddington Group, a division of Newell Brands (an $850 million per
year disposable packaging manufacturer), President of B+H North
America (a $400 million per year division of the AptarGroup),
President of Rigid Closed Top (an ~$1B per year division of Berry
Plastics Corporation), and executive sales and marketing roles at
leading specialty market corporations.
Mr. Scheu will be instrumental in leading
Sharps’ marketing initiatives as the Company advances from research
and development to commercial revenue. His initial focus will be
leading sales efforts around Sharps’ commercial-ready Securegard®,
a disposable smart safety syringe product offering with multiple
configurations. Mr. Scheu will lead the efforts around
commercialization and contracts with customers within the retail
pharmacy space to support the efforts around the introduction of
Sharps’ technology to healthcare customers, which include hospital
networks. Sharps recently announced a qualification agreement with
a major medical device company for its smart safety syringe
technology that could drive increased commercial revenue in 2023.
The agreement will begin with the 1mL and 3mL Securegard® product
line and will be followed by Sologard® Luer lock syringes for
larger volume drug applications. The qualification agreement will
allow for the opportunity to create secondary sales agreements with
additional key hospital networks, which Mr. Scheu will oversee.
In conjunction with the vial-draw product
launch, Sharps is also preparing for the commercialization of its
next-generation polymer-based prefilled syringe systems, which will
be the Company’s future growth driver. Technical and commercial
resources will be added to Mr. Scheu’s prefilled product team, and
Sharps will begin manufacturing from the Inject-EZ facility in
Columbia, South Carolina. Through Mr. Scheu’s deep expertise in
plastics operations and sales, he will play an integral role in
supporting the partnership with Nephron Pharmaceuticals.
About Sharps TechnologySharps
Technology is a medical device and pharmaceutical packaging company
specializing in the development and manufacturing of innovative
drug delivery systems. The Company’s product lines focus on low
waste and ultra-low waste syringe technologies that incorporate
both passive and active safety features. These features protect
front line healthcare workers from life-threatening needle stick
injuries and protect the public from needle re-use. Sharps
Technology has extensive expertise in specialized prefilled syringe
systems and ready to use processing. The Company has a
manufacturing facility in Hungary and has partnered with Nephron
Pharmaceuticals to expand its manufacturing capacity in the U.S.
For additional information, please
visit www.sharpstechnology.com.
Forward-Looking Statements:This
press release contains “forward-looking statements”.
Forward-looking statements reflect our current view about future
events. When used in this press release, the words “anticipate,”
“believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the
negative of these terms and similar expressions, as they relate to
us or our management, identify forward-looking statements. Such
statements, include, but are not limited to, statements contained
in this press release relating to our business strategy, our future
operating results and liquidity, and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy, and other
future conditions. Because forward–looking statements relate to the
future, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended, or planned. Factors or events that could cause
our actual results to differ may emerge from time to time, and it
is not possible for us to predict all of them. We cannot guarantee
future results, levels of activity, performance, or achievements.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
Investor Relations:US Investor
Relations: Adam Holdsworth, Managing
DirectorTraDigital IRadam@tradigitalir.com
Grafico Azioni Sharps Technology (NASDAQ:STSS)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Sharps Technology (NASDAQ:STSS)
Storico
Da Set 2023 a Set 2024